NLS Pharmaceutics (NASDAQ:NLSP) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of NLS Pharmaceutics (NASDAQ:NLSP) from a sell rating to a hold rating in a research note published on Sunday morning.

NLS Pharmaceutics Price Performance

Shares of NASDAQ:NLSP opened at $2.19 on Friday. The business has a 50-day moving average price of $2.16 and a 200 day moving average price of $1.98. NLS Pharmaceutics has a 12-month low of $1.30 and a 12-month high of $5.95.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).